Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 4
1975 4
1976 4
1977 8
1978 9
1979 1
1983 1
1985 2
1988 1
1990 1
1992 2
2005 1
2006 3
2007 2
2008 3
2009 2
2010 1
2011 2
2012 1
2014 1
2016 1
2017 3
2018 1
2019 7
2020 5
2021 7
2022 12
2023 4
2024 4
2025 10

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

102 results

Results by year

Filters applied: . Clear all
Page 1
Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: results from an open-label, multicentre, phase 1/2 study.
Jain H, Karulkar A, Kalra D, Ravikumar S, Shah S, Firfiray A, Pendhari J, Jaiswal AK, Khan A, Sundharam M, Vaibhaw A, Saroha A, Rajyopadhye S, Basu M, Asija S, Chowdhury A, Beher R, Banik A, Dwivedi A, Purwar S, Narula G, Banavali S, Jain N, Highfill SL, Stroncek D, Fry T, Melinkeri S, Wilson L, Agarwal N, Aribandi A, Boyella PK, Shah NN, Neelapu SS, Sengar M, Purwar R; CAR-T clinical trial group. Jain H, et al. Among authors: purwar r. Lancet Haematol. 2025 Apr;12(4):e282-e293. doi: 10.1016/S2352-3026(24)00377-6. Epub 2025 Mar 13. Lancet Haematol. 2025. PMID: 40090352 Clinical Trial.
Novel humanized CD19-CAR-T (Now talicabtagene autoleucel, Tali-cel™) cells in relapsed/ refractory pediatric B-acute lymphoblastic leukemia- an open-label single-arm phase-I/Ib study.
Narula G, Keerthivasagam S, Jain H, Punatar S, Chichra A, Dhamne C, Tembhare P, Subramanian PG, Patkar N, Poojary M, Gokarn A, Mirgh S, Jindal N, Nisar A, Pandit D, Pandit K, Dwivedi A, Karulkar A, Jaiswal AK, Khan A, Shah S, Rafiq A, Basu M, Pendhari J, Asija S, Chowdury A, Banik A, Moulik NR, Srinivasan S, Bhosle S, Hiregoudar S, Ojha S, Nayak L, Thorat J, Bagal B, Sengar M, Khattry N, Banavali S, Highfill S, Shah NN, Purwar R. Narula G, et al. Among authors: purwar r. Blood Cancer J. 2025 Apr 24;15(1):75. doi: 10.1038/s41408-025-01279-9. Blood Cancer J. 2025. PMID: 40274761 Free PMC article. Clinical Trial.
Genetic alterations and oxidative stress in T cell lymphomas.
Kumar S, Dhamija B, Attrish D, Sawant V, Sengar M, Thorat J, Shet T, Jain H, Purwar R. Kumar S, et al. Among authors: purwar r. Pharmacol Ther. 2022 Aug;236:108109. doi: 10.1016/j.pharmthera.2022.108109. Epub 2022 Jan 7. Pharmacol Ther. 2022. PMID: 35007658 Review.
A proteogenomic approach to target neoantigens in solid tumors.
Verma A, Halder A, Marathe S, Purwar R, Srivastava S. Verma A, et al. Among authors: purwar r. Expert Rev Proteomics. 2020 Nov-Dec;17(11-12):797-812. doi: 10.1080/14789450.2020.1881889. Expert Rev Proteomics. 2020. PMID: 33491499 Review.
102 results